UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 159

Sortiert nach

Evaluation of a Three-Dimensional Primary Human Hepatocyte Spheroid Model: Adoption and Industrialization for the Enhanced Detection of Drug-Induced Liver Injury

Chemical research in toxicology, 2021-12, Vol.34 (12), p.2485-2499

2021

Volltextzugriff (PDF)

Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds

Chemical research in toxicology, 2012-10, Vol.25 (10), p.2067-2082

2012

Volltextzugriff (PDF)

Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans

Drug metabolism and disposition, 2014-03, Vol.42 (3), p.415

2014

Volltextzugriff (PDF)

An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development

Chemico-biological interactions, 2011-06, Vol.192 (1), p.60-64

2011

Volltextzugriff (PDF)

Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure

Molecular pharmacology, 2013-05, Vol.83 (5), p.919-929

2013

Volltextzugriff (PDF)

The identification of clinical candidate SB-480848 : A potent inhibitor of lipoprotein-associated phospholipase A2

Bioorganic & medicinal chemistry letters, 2003-03, Vol.13 (6), p.1067-1070

2003

Volltextzugriff (PDF)

A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study

British journal of clinical pharmacology, 2023-03, Vol.89 (3), p.1187-1197

2023

Volltextzugriff (PDF)

Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial

BMJ (British Medical Journal), 2007-07, Vol.335 (7610), p.83-87

International edition, 2007

Volltextzugriff (PDF)

Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations

Drug metabolism and disposition, 2020-04, Vol.48 (4), p.307-316

2020

Volltextzugriff (PDF)

Glaring Disproportionality in the Court and Judicial Processing of Racially and Ethnically Diverse Youth Offender Cases: A Study of Contrasts

Taylor, Maxine Jacqueline

2021

Volltextzugriff (PDF)

Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial

The Lancet (British edition), 2004-06, Vol.363 (9424), p.1854-1859

2004

Volltextzugriff (PDF)

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects

Antimicrobial agents and chemotherapy, 2016-12, Vol.60 (12), p.7321-7332

2016

Volltextzugriff (PDF)

The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man

Bioorganic & medicinal chemistry letters, 2002-09, Vol.12 (18), p.2603-2606

2002

Volltextzugriff (PDF)

Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound

The AAPS journal, 2018-07, Vol.20 (4), p.74-74, Article 74

2018

Volltextzugriff (PDF)

Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists

Journal of medicinal chemistry, 2015-10, Vol.58 (20), p.8236-8256

2015

Volltextzugriff (PDF)

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

The lancet child & adolescent health, 2022-02, Vol.6 (2), p.86-95

2022

Volltextzugriff (PDF)

Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P 1 Agonists

Journal of medicinal chemistry, 2015-10, Vol.58 (20), p.8236-8256

2015

Volltextzugriff (PDF)

1-(Arylpiperazinylamidoalkyl)-pyrimidones : Orally active inhibitors of lipoprotein-associated phospholipase A2

Bioorganic & medicinal chemistry letters, 2001-07, Vol.11 (14), p.1925-1929

2001

Volltextzugriff (PDF)

Peer Support and Breastfeeding Intentions Among Black WIC Participants

Journal of human lactation, 2009-05, Vol.25 (2), p.157-162

2009

Volltextzugriff (PDF)

Gender-based wage differentials among registered dietitians

The health care manager, 2007-01, Vol.26 (1), p.52

2007

Volltextzugriff (PDF)

Sex differences in health care: the compensation experience of registered dietitians

The health care manager, 2008-07, Vol.27 (3), p.259

2008

Volltextzugriff (PDF)

Exploring debridement options for chronic venous leg ulcers

British journal of nursing (Mark Allen Publishing), 2005-04, Vol.14 (7), p.393

2005

Volltextzugriff (PDF)

The correlation between religiosity and moral development: The impact of conservative Christian higher education on moral reasoning of medical students

Taylor, Maxine

2005

Volltextzugriff (PDF)

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A 2

Bioorganic & medicinal chemistry letters, 2003, Vol.13 (6), p.1067-1070

2003

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(133)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(158)
Japanisch
(18)
Deutsch
(1)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(78)
Humans
(70)
Female
(43)
Male
(39)
Biological And Medical Sciences
(34)
Medical Sciences
(28)
Adult
(24)
Aged
(24)
Middle Aged
(24)
Pharmacology & Pharmacy
(20)
Psychiatry
(20)
Animals
(16)
Pharmacology. Drug Treatments
(15)
Psychology. Psychoanalysis. Psychiatry
(13)
Adolescent
(12)
Aged, 80 And Over
(12)
Young Adult
(12)
Antipsychotic Agents - Administration & Dosage
(11)
Neuropharmacology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of a Three-Dimensional Primary Human Hepatocyte Spheroid Model: Adoption and Industrialization for the Enhanced Detection of Drug-Induced Liver Injury

Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds

Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans

An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development

Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure

The identification of clinical candidate SB-480848 : A potent inhibitor of lipoprotein-associated phospholipase A2

A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study

Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations

Glaring Disproportionality in the Court and Judicial Processing of Racially and Ethnically Diverse Youth Offender Cases: A Study of Contrasts

Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects

The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man

Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound

Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P 1 Agonists

1-(Arylpiperazinylamidoalkyl)-pyrimidones : Orally active inhibitors of lipoprotein-associated phospholipase A2

Peer Support and Breastfeeding Intentions Among Black WIC Participants

Gender-based wage differentials among registered dietitians

Sex differences in health care: the compensation experience of registered dietitians

Exploring debridement options for chronic venous leg ulcers

The correlation between religiosity and moral development: The impact of conservative Christian higher education on moral reasoning of medical students

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A 2

Suchergebnisse filtern